The genetic basis of severe combined immunodeficiency and its variants by Tasher D & Dalal I
© 2012 Tasher and Dalal, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
The Application of Clinical Genetics 2012:5 67–80
The Application of Clinical Genetics
The genetic basis of severe combined 
immunodeficiency and its variants
Diana Tasher1,2
Ilan Dalal1,2
1The Pediatric Infectious and 
Immunology Unit, E Wolfson 
Medical Center, Holon, Israel; 2The 
Sackler School of Medicine, Tel Aviv 
University, Tel Aviv, Israel
Correspondence: Ilan Dalal 
Pediatric Infectious and Immunology Unit, 
E Wolfson Medical Center, POB 5,  
Holon 58100, Israel 
Tel +972 3 5028302 
Fax +972 3 5028164 
Email ilandalal@hotmail.com
Abstract: Severe combined immunodeficiency (SCID) syndromes are characterized by a block 
in T lymphocyte differentiation that is variably associated with abnormal development of other 
lymphocyte lineages (B and/or natural killer [NK] cells), leading to death early in life unless 
treated urgently by hematopoietic stem cell transplant. SCID comprises genotypically and phe-
notypically heterogeneous conditions, of which the genetic basis for approximately 85% of the 
underlying immunologic defects have been recently elucidated. A major obstacle in deciphering 
the pathogenesis of SCID syndromes is that different mutations in a single gene may give rise 
to distinct clinical conditions and that a similar clinical phenotype can result from mutations in 
different genes. Mutation analysis is now an important component of the complete evaluation 
of a patient with SCID since it has a dramatic impact on many aspects of this potentially life-
threatening disease such as genetic counseling, prenatal diagnosis, modalities of treatment, and, 
eventually, prognosis. Dr Robert Good, one of the founders of modern immunology, described 
the SCID syndrome as “experiments of nature.” By understanding the cellular and genetic 
basis of these immunodeficiency diseases and, eventually, normal immunity, we optimize the 
“bedside to research laboratory and back again” approach to medicine.
Keywords: severe combined immune deficiency, molecular defects, lymphocytes
Human severe combined immunodeficiency (SCID) comprises a group of genotypi-
cally and phenotypically heterogeneous diseases. The clinical presentation usually 
includes severe, recurrent, and potentially lethal infections early in infancy such 
as chronic diarrhea, failure to thrive, lymphopenia (particularly of T lymphocytes) 
with profound abnormalities of cell-mediated immunity, and antibody deficiency. 
Skin rashes might reflect graft-versus-host disease caused by maternal T-cell 
engraftment in infants with SCID or tissue damage caused by the infiltration of 
activated, autologous T lymphocytes, as is typically seen in Omenn syndrome 
(OS). In addition, some forms of SCID are associated with distinctive features in 
other systems.1
SCID is a syndrome caused by mutations in different genes whose products are 
crucial for the development and function of both T and B cells. In some cases, the 
molecular defect prevents only T-cell function, while B cells are normal. Natural killer 
(NK) cells, a lymphocyte subset exhibiting cytotoxic activities, develop via a pathway 
that is distinct from B and T cells. NK cells are present in approximately 50% of patients 
with SCID, and provide a degree of protection against bacterial and viral infections in 
these patients, and, ultimately, a better prognosis.
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SCID immunophenotypes can be classified according 
to the presence (T–B+ SCID) or absence (T–B− SCID) of 
B cells in the peripheral blood. Both main groups of SCID 
include forms with or without NK lymphocytes.
SCID can also be categorized based on the cellular function 
of the protein that is encoded by the defective gene. The five 
functional categories include proteins involved in cytokine 
signaling, antigen presentation, V(D)J recombination, T-cell 
receptor (TCR) signaling, and basic cellular functions.
SCID syndromes have a prevalence of approximately 
1:50,000 live births and are more common in male   subjects, 
reflecting the overrepresentation of X-linked SCID 
(XL-SCID), the most common worldwide form (∼50%) of 
SCID in human subjects.1–3
However, in cultures in which consanguineous marriage 
is common, the incidence of autosomal recessive (AR) SCID 
is higher than has been previously reported.4,5
Gene defects are present in approximately 85% of SCID 
cases.1 Thus, mutation analysis in the characterization of SCID 
is now an important component of the complete evaluation 
of a patient, particularly as affected genes associated with 
this group of diseases continue to increase. In addition, it has 
a dramatic impact on many aspects of this potentially life-
  threatening disease such as genetic counseling, prenatal diag-
nosis, modalities of treatment, and, eventually, prognosis.
Normal T -cell development  
and activation
Before discussing the different types of SCID phenotypes, 
one should describe the normal steps involved in T-cell devel-
opment, maturation, differentiation, and activation. Each 
step in the normal process that generates normal, functional   
T cells is genetically controlled by many structural and regu-
latory genes, and, therefore, the potential for genetic defects 
resulting in an abnormal number or function of  T cells – and 
subsequently, SCID phenotype – is great.
Pluripotential hematopoietic stem cells develop into 
  lymphoid stem cells, which differentiate into T, B, or NK 
cells depending on the organs or tissues to which these stem 
cells migrate. T-cell progenitors occur in the embryonic 
thymus as early as 8 weeks of gestation and, by the age 
of 10 weeks, 25% of thymocytes bear the mature, specific 
T-cell receptor (TCR). TCRs consist of two chains (α and β)   
that are coexpressed on the cell surface with CD3 – a mul-
tichain signaling complex of five polypeptides: γ, δ, ε, ζ, 
and η. Together, the TCR and the CD3 molecule form the 
TCR   complex. This complex also includes tyrosine phos-
phatase CD45, which is found on all hematopoietic cells 
and is essential for the normal maturation of T cells. Early 
development of TCR in the thymus requires the expression 
of specific markers such as CD1, CD2, and interleukin   
2 receptor (IL-2R) molecules, which serve critical receptor–
ligand functions during the early stages of ontogeny. The next 
step involves the lymphoid-specific recombinase activating 
genes (RAG)1 and RAG2, which are responsible for the V(D)J 
rearrangement process, and are critical for the normal devel-
opment of TCRs. As immature cortical thymocytes begin to 
express TCRs, they move through the processes of positive 
and negative selection. Mature T cells that survive positive 
selection either express CD4 and are restricted to interact-
ing only with self class II molecules or express CD8 and are 
restricted to interacting with self class I human histocompat-
ibility leukocyte antigens (HLAs). The purpose of negative 
selection is to remove autoreactive T cells and, subsequently, 
by the end of the process, 97% of all cortical thymocytes 
die. During negative selection, mature single positive T cells 
emigrate from the thymus to secondary lymphoid organs 
such as the spleen, lymph nodes, tonsils, and appendix at 12 
weeks of embryonic life. Immune cell interaction is crucial 
for the adequate response and activation of T cells, since 
TCRs can only recognize processed antigenic peptides, 
presented to it by antigen-presenting cells (APCs) such as 
B cells, macrophages, and dendritic cells, in the context 
of class I or II HLA molecules. Normal activation of CD4 
T cells by B cells requires a transient expression of CD40 
ligand molecules on the surface of CD4 T cells, which bind to 
CD40 molecules on B cells. The TCR then interacts with the 
peptide-bearing HLA molecule and, through the multichain, 
CD3 signaling complex, sends a signal to produce cytokines, 
ultimately resulting in T-cell activation and proliferation. The 
most important cytokine involved in the activation and pro-
liferation of T cells is IL-2, which binds to its high affinity, 
multi-chain (α, β, γ) receptor; namely, IL-2R.
Activation of the TCR complex results in the following 
  activation events: (1) Production of lipid mediators such as 
inositol triphosphate and diacylglycerol and activation of protein 
kinase C. (2) Phosphorylation and activation of tyrosine kinases 
such as Lck and ZAP-70. (3) Elevation of intracellular calcium 
levels. All these activation events convey messages to the cell 
nucleus resulting in the normal functioning of T cells.6,7
Although it is more appropriate to refer to SCID syn-
dromes according to the specific molecular defect (once it 
has been identified), phenotypic classification is still viewed 
as a simpler, more useful, and more intuitive approach. 
Thus, we decided to take this approach in order to classify 
the different types of SCID (Table 1). However, some forms 
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Table 1 Classification of SCID syndromes based on immunophenotype
Inheritance Phenotype 
MIM number
Gene/locus 
MIM number
Specific manifestations
T-B-NK-
Adenosine deaminase  
(ADA) deficiency
AR 102700 608958 Costochondral junction flaring, neurological 
features, hearing impairment, liver injury  
May present with Omenn syndrome
Reticular dysgenesis AR 267500 103020 Profound neutropenia, deafness
T-B-NK+
RAG1/2 deficiency AR 601457 179615, 179616 May present with Omenn syndrome. 
Hypomorphic mutations have been associated 
with a granuloma formation,  
and EBv-related lymphoma
DCLRE1C (Artemis)  
deficiency
AR 602450 605988 Radiation sensitivity. May present with 
Omenn syndrome
DNA-PKcs deficiency AR 600899 Radiation sensitivity
T-B+NK-
Common gamma chain 
(γc) deficiency
XL 300400 308380 Growth failure. May present with 
Omenn syndrome or polymorphous 
lymphoproliferative disorder
JAK3 deficiency AR 600802 600173
T-B+NK+
IL7Rα deficiency AR 600802 146661 May present with Omenn syndrome.
Coronin-1 A deficiency AR 605000 Detectable thymus
CD45 deficiency AR 202500 151460 Normal γ/δ T cells
CD3δ/ CD3ε/CD3ζ 
deficiency
AR 608971 186790, 186830,  
186780
No γ/δ T cells. Autoimmune manifestations 
are common
Abbreviations: SCID, severe combined immune deficiencies; XL, X-linked inheritance; AR, autosomal recessive inheritance; RAG, recombination activating gene; DCLRE1C, 
DNA crosslink repair 1C; DNA-PKcs, DNA protein kinase catalytic subunit; JAK3, Janus activating kinase 3; IL7Rα, IL-7 receptor α-chain; EBv, Epstein–Barr virus.
of SCID do not fit into this classification and, therefore, we 
will use the alternative approach involving cellular function 
for characterization of these forms (Table 2).
T−B−NK− SCID
The two identified T−B−NK− SCID forms are adenosine 
deaminase (ADA) deficiency and reticular dysgenesis (RD). 
Impaired survival of lymphocyte precursors is observed in 
both forms.
ADA deficiency
With an incidence of 1 in 200,000 live births, ADA defi-
ciency accounts for approximately one-third of all cases 
of AR SCID and approximately 15% of all cases of SCID. 
ADA deficiency is caused by mutations in the ADA gene at 
20q13.11.8 ADA is an enzyme of the purine salvage pathway 
that mediates conversion of adenosine (and deoxyadenosine) 
to inosine (and deoxyinosine). In the absence of functional 
ADA, there is an intracellular accumulation of the phos-
phorylated metabolites of adenosine and deoxyadenosine. 
These products are toxic to lymphoid precursors in the bone 
marrow and thymus. Approximately 90% of ADA-deficient 
individuals have a classic severe SCID phenotype and they 
develop severe infections in the first months of life. Most of 
the remainder has a “delayed” or “late onset” form that pres-
ents in late infancy or early childhood. The wide spectrum of 
the ADA-deficiency phenotype is largely related to the vari-
ability in genetic mutations. Clinical manifestations of ADA 
deficiency extend beyond the immune system (deafness, 
behavioral problems, cognitive deficits, gait abnormalities, 
costochondral abnormalities, and liver toxicity), reflecting 
the fact that ADA is a housekeeping enzyme.7,8
The definitive treatment of choice is hematopoietic stem 
cell (HSC) transplantation from an HLA identical sibling 
or other appropriate donor such as one who is unrelated. 
Enzyme replacement therapy with polyethylene glycol–ADA 
(PEG–ADA) is an effective, alternative therapeutic approach 
in some patients without an appropriate donor. There is a 
lack of data regarding the effect of PEG–ADA treatment on 
neurologic abnormalities.9 ADA SCID was the first human 
disease treated by gene therapy.
Reticular dysgenesis
This form is one of the rarest and most severe types of 
SCID. Severe infections occur earlier than in other forms of 
SCID due to profound neutropenia, in addition to markedly 
decreased T and NK cells. B cells are absent to low normal. In 
addition, patients with RD also have sensorineural deafness.10 
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Table 2 Classification of SCID variants based on normal T-cell development
Inheritance Phenotype 
MIM number
Gene/locus 
MIM number
Specific manifestations
DNA ligase IV deficiency AR 606593 601837 Microcephaly, developmental delay, facial 
dysmorphism, radiation sensitivity. May present with 
Omenn syndrome or with a delayed clinical onset
Cernunnos deficiency AR 611291 611290 Microcephaly, developmental delay, in utero growth 
retardation, radiation sensitivity
CD3γ deficiency AR 186740 May present with a benign course
MHC class I deficiency AR 604571 170260, 170261,  
601962
Necrotizing granulomatous skin lesions
CD8 deficiency AR 608957 186910
MHC class II deficiency AR 209920 600005, 601863, 
601861, 603200
Interleukin-2 receptor alpha 
chain (CD25) deficiency
AR 606367 147730 Lymphocytic infiltration of tissues (lung, liver, gut, and 
bone), autoimmunity (may resemble IPEX syndrome)
p56lck deficiency AR 153390
ZAP-70 deficiency AR 176947
Ca++ channel deficiency AR 612782 
612783
610277 
605921
Anhydrotic ectodermic dysplasia, nonprogressive 
myopathy, abnormalities in dental enamel. Unique 
features of STIM1 deficiency: autoimmunity and 
partial iris hypoplasia
Signal transducer and 
activator of transcription 
5b (STAT5b) deficiency
AR 245590 604260 Growth-hormone insensitive dwarfism, dysmorphic 
features, eczema, and autoimmunity
Winged-helix nude  
(FOXN1) deficiency
AR 601705 600838 Congenital alopecia, and nail dystrophy, abnormal 
thymic epithelium
Purine nucleoside 
phosphorylase deficiency 
(PNP)
AR 613179 164050 Autoimmune hemolytic anemia, neurological 
impairment, and neoplasia
CD40 ligand deficiency XL 308230 300386 Neutropenia, thrombocytopenia; hemolytic anemia, 
biliary tract and liver disease, lymphoproliferative 
disease, and increased rates of malignancy
CD40 deficiency AR 606843 109535 Neutropenia, gastrointestinal and liver/biliary tract 
disease
Itk deficiency AR 613011 186973 EBv- associated lymphoproliferation
Dedicator of cytokinesis 8 
(DOCK8) deficiency
AR 243700 611432 Extensive cutaneous viral and bacterial infections, 
susceptibility to cancer, hypereosinophilia, severe 
atopy, low NK cells
Abbreviations:  SCID,  severe  combined  immune  deficiencies;  XL,  X-linked  inheritance;  AR,  autosomal  recessive  inheritance;  NK,  natural  killer  cells;  MHC,  major 
histocompatibility complex; IPEX, immune dysregulation polyendocrinopathy enteropathy (X-linked); lck, lymphocyte-specific protein tyrosine kinase; ZAP70, zeta chain-
associated 70-kDa protein kinase; FOXN1, forkhead box protein N1; Itk, IL-2-inducible T-cell kinase; EBv, Epstein–Barr virus.
This AR SCID is caused by mutations in the mitochondrial 
adenylate kinase (AK)2 gene. This enzyme regulates levels of 
adenosine diphosphate. AK2 deficiency results in increased 
apoptosis of myeloid and lymphoid precursors.10
T−B−NK+ SCID
All the known causes for T−B−NK+ SCID syndromes 
involve defects in V(D)J recombination. This form of AR 
SCID phenotype accounts for 20% to 30% of all cases of 
SCID.11 It includes defects in RAG1 and RAG2, Artemis 
(DCLRE1C), and the DNA protein kinase catalytic   subunit 
(DNA-PKcs).12,13 There are two principal types of patients 
with T−B−NK+ SCID associated with V(D)J recombination 
defects – those with and without radiation sensitivity.
RAG1/RAG2
Mutations in these genes are not associated with radiation 
sensitivity since these genes are expressed exclusively in 
  lymphocytes and mediate the creation of double-strand 
DNA breaks at the sites of recombination and in signal 
sequences during T- and B-cell receptor gene rearrangement. 
  Nonhomologous end joining (NHEJ), which is a common 
machinery repair process found in many other tissues, is 
normal in individuals with RAG1 or RAG2 defects. Certain 
RAG mutations that result in partial protein expression and 
limited production of T and B cells are known to cause OS.14,15 
Hypomorphic RAG mutations have also been associated with 
a novel phenotype characterized by granuloma formation, 
EBV-related lymphoma, and survival into late childhood.15
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According to our local experience, XL-SCID is rare in 
Israel, while the most common phenotype is T−B− SCID 
due to RAG1/RAG2 mutations. This phenomenon is   probably 
due to the high rate of consanguinity among our Arab-origin 
population, which accounts for approximately 20% of the 
whole population, and for more than 50% of our SCID 
patients.16,17
Artemis and DNA-PKcs lead to increased sensitivity to 
ionizing radiation, since these gene products are important 
in the process of NHEJ required for repair of double-strand 
DNA breaks caused by radiation.
Artemis
Artemis deficiency is also known as Athabascan SCID 
(SCIDA), since a founder mutation in Artemis is found with 
increased frequency in Native Americans speaking one of 
the Athabascan family languages (eg, Apache, Navajo).18 
In addition to T-cell maturation arrest, mutations in the 
Artemis gene result in B-cell differentiation arrest at the 
pre-B-cell-receptor checkpoint.19
DNA-PKcs
DNA-PKcs regulates Artemis by both phosphorylation and 
complex formation to permit enzymatic activities that are 
critical for V(D)J recombination and for NHEJ.
Intriguingly, the described functional missense DNA-
PKcs mutation does not affect either DNA-PKcs kinase 
activity or autophosphorylation – an important event that 
remodels the protein. Yet the clinical and cellular phenotype 
is similar to that caused by Artemis deficiency, suggesting that 
the mutation precludes Artemis activation, an event known 
to be DNA-PKcs dependent.20
T−B+NK− SCID
Gene mutations affecting the integrity of the common 
gamma chain (γc)/JAK3 signaling pathway result in the 
most common form of inherited T−B+NK− SCID. Despite 
the presence of normal numbers of B cells, cell activation, 
proliferation, and differentiation are impaired, resulting in 
profound hypogammaglobulinemia.
X-linked SCID
This form of SCID is due to defects in γc. Mutations in this 
gene lead to profound derangement of the immune system 
via the blockade of multiple cytokine pathways (IL-2Rγc 
is shared by the receptors of IL-4, IL-7, IL-9, IL-15, and 
IL-21), which are important for lymphocyte development 
and function.21,22 In particular, IL-7 mediates expansion of 
early thymocyte progenitors, whereas IL-15 plays a role in 
NK cell development. Accordingly, patients with XL-SCID 
lack both T and NK cells, whereas they have a normal number 
of circulating B lymphocytes.23
XL-SCID patients usually have the classic clinical 
SCID phenotype. However, some patients have an atypical 
presentation such as an OS phenotype24 or a polymorphous 
lymphoproliferative disorder with Hodgkin-like features.25 
The γc subunit is also involved in growth hormone-receptor 
signaling. Thus, growth failure seen in children with XL-
SCID may also be due to the underlying genetic defect.26 
The γ chain mediates signal transduction via its physical 
association with a member of the Janus family of protein 
kinases, JAK3.27 The primary therapy currently available for 
XL-SCID is hematopoietic cell transplantation. Of note is 
that, in some cases, gene therapy has been successful.
JAK3 deficiency
JAK3 (encoded on chromosome 19p12-13.1) mediates 
cytokine signal transduction and is essential for lymphoid 
cell development. SCID due to JAK3 deficiency is rare, 
accounting only for approximately 6% of all cases of SCID. 
This AR form of T−B+NK− SCID is identical to XL-SCID 
in cellular and clinical phenotypes. Rarely, partial JAK3 
defects associated with low amounts of functional protein 
can present with mild immunodeficiency.27
T−B+NK+ SCID
This SCID phenotype includes defects in the IL-7 receptor 
alpha chain (IL-7Rα; also called CD127), actin-regulating 
protein, coronin 1A (CORO1A), CD45 (also called protein-
tyrosine phosphatase receptor-type C; PTPRC), and the CD3 
chains: CD3 delta (CD3D), CD3 epsilon (CD3E), and CD3 
zeta (CD3Z).
IL-7Rα chain deficiency
This defect is the third most common type of SCID. IL-7Rα 
(encoded on chromosome 5p13) plays a critical role in 
cytokine signaling that is necessary for T-cell   development. 
Although both T-cell and B-cell progenitors express the 
functional IL-7 receptor that consists of IL-7Rα and a 
γc chain, this lymphocyte-receptor system is critical for 
the T lineage, but not for the B lineage, or for NK-cell 
development. IL-15 promotes NK-cell differentiation and 
maturation. Many patients have been identified with a 
  classic SCID phenotype and they lack the IL-7Rα chain.28,29 
Mutations in the IL-7Rα gene can also present with an OS 
phenotype.30
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Actin-regulating protein coronin  
1A deficiency
Coronin 1A (encoded on chromosome 16p11.2) is involved 
in actin cytoskeleton regulation and is essential for T-cell 
immigration from the thymus to the secondary lymphoid 
organs. Defects in Coronin 1A lead to an absence of normal 
peripheral T cells and to a classic SCID phenotype. The 
  thymus is present, unlike in most other forms of SCID.31
CD45 deficiency
CD45, the leukocyte common antigen (encoded on chromo-
some 1q31-q32) is a transmembrane tyrosine phosphatase 
involved in TCR signaling and T-cell development in the 
thymus. Only a few patients have been identified with classic 
SCID due to CD45 deficiency.32
CD3 complex component 
deficiencies
The CD3 complex plays a major role in signaling through 
the TCR, which is essential for the normal maturation of   
T cells. Mutations in the genes encoding CD3 chains (CD3 
delta, CD3 epsilon, and CD3 zeta) appear to have an AR 
pattern of inheritance and have been reported in several 
patients. The clinical features are highly variable, depending 
upon the affected chain and mutation. Hypomorphic muta-
tions in genes that are typically associated with SCID can 
allow residual T-cell development. In these cases, impaired 
cross-talk between thymocytes and thymic epithelial cells 
might compromise mechanisms of central tolerance, with 
failure to delete autoreactive T cells, and with impaired gen-
eration of regulatory T (Treg) cells. Accordingly, autoim-
mune manifestations are common, with infiltration of target 
tissues by activated and oligoclonal T lymphocytes.33–35
Omenn syndrome
OS is characterized by early postnatal diffuse exfoliative 
erythroderma, protracted diarrhea, lymphadenopathy, and 
hepatosplenomegaly, together with the typical recurrent 
severe infections. Laboratory investigations reveal prominent 
eosinophilia and lymphocytosis, mainly of T cells. These 
lymphocytes exhibit activation markers despite their highly 
restricted repertoire. Variable hypogammaglobulinemia with 
elevated levels of immunoglobulin E (IgE) and skewing 
toward TH2, the absence of B cells with minimal antibody 
response, and the absence of normal mitogenic responses are 
some of the common immune abnormalities in this   syndrome. 
This peculiar phenotype was found to be associated with 
several different gene mutations including RAG1/2 and   
Artemis, IL-7Rα, RNA-processing endoribonuclease, DNA 
ligase IV , ADA, and γc.15,36
T+B+NK+ SCID
Other forms of combined immunodeficiency have many 
of the elements of the clinical presentation of SCID, 
  including opportunistic infections. These forms of   combined 
  immunodeficiency are usually distinguished by   distinctive 
laboratory features and other elements of the clinical 
  presentation. However, in some cases, the distinction 
between SCID and combined immunodeficiency (CID) is 
only made by molecular testing.
In this chapter, we took the approach of dissecting 
the different types of SCID based on the normal process 
of   development, activation, and maturation of T cells 
as described previously (Figure 1). Defects in T-cell 
  development that occur beyond the CD4+ CD8+ double-
positive cell stage result in SCID with residual numbers of T 
lymphocytes. These SCID variants include: DNA ligase IV; 
Cernunnos-XLF; CD3γ deficiency; MHC class I deficiency; 
CD8 deficiency; MHC class II deficiency; IL-2 receptor 
alpha chain (CD25) deficiency; p56lck deficiency; ZAP-
70 deficiency; ORAI1/CRACM1 and STIM1 deficiencies; 
  signal transducer and activator of transcription 5b (STAT5b) 
deficiency; winged-helix nude (FOXN1) deficiency; PNP; 
CD40 and CD40 ligand deficiencies; Itk; and dedicator of 
cytokinesis 8 (DOCK8) deficiency.
DNA ligase IV (LIG4)
The DNA ends must be ligated as part of the DNA repair 
  process and this is implemented by an LIG4-XRCC4 complex. 
XRCC4 (X-ray-complementing Chinese hamster gene 4) has 
no known enzymatic activity, but functions as a scaffolding 
protein that helps attract other repair proteins to the DNA break. 
XRCC4 stabilizes LIG4 and enhances its activity.
Patients with LIG4 syndrome present with microcephaly, 
developmental delay, facial dysmorphism, increased suscep-
tibility to tumors, and a variable degree of immunodeficiency 
that ranges from SCID/OS, to hypogammaglobulinemia with 
impaired class-switch recombination, to moderate, or even 
very modest defects in T- and B-cell immunity.37–39
Cernunnos–XLF
Defects in the NHEJ factor 1 gene (NHEJ1 gene) that codes 
for the protein Cernunnos, also known as the XRCC4-like 
factor (XLF), lead to a T−B−NK+ radiation-sensitive 
SCID phenotype with associated developmental delay 
and   microcephaly. T cells are absent, except for memory 
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Figure 1 Genes with mutations that cause monogenic, severe T-cell immunodeficiency in humans can be intrinsic to the thymic epithelium or to T cells. (A) Genetic defects 
that are intrinsic to thymic epithelial cells ultimately affect the antigen-presentation pathway. (B) Genetic defects that are intrinsic to T cells include those that affect T-cell 
receptor (TCR) signaling, cytokine signaling, somatic recombination, or basic cellular processes. Other genes that are important to these pathways or processes, but have not 
been linked to severe T-cell deficiency in humans are shown in grey. Copyright © 2008. Nature Publishing Group. Adapted with permission from Liston A, Enders A, Siggs 
OM. Unravelling the association of partial T-cell immunodeficiency and immune dysregulation. Nat Rev Immunol. 2008;8:546.80
Abbreviations: ADA, adenosine deaminase; ATM, ataxia-telangiectasia mutated; CBL, Casitas B-lineage lymphoma; CIITA, class II transactivator; DCLRE1C, DNA crosslink 
repair 1C; DNMT3β, DNA cytosine-5 methyltransferase 3β; ER, endoplasmic reticulum; FOXN1, forkhead box N1; GADS, GRB2-related adaptor protein; IL-2RΓ, IL-2 
receptor Γ-chain; IL-7, interleukin-7; IL-7Rα, IL-7 receptor α-chain; JAK, Janus kinase; LAT, linker for activation of T cells; LIG4, ligase Iv; MRE11A, meiotic recombination 11 
homolog A; Nibrin, Nijmegen breakage syndrome 1; NP, nucleoside phosphorylase; CRACM1, calcium release-activated calcium modulator 1; RAG, recombination-activating 
gene; RFX5, regulatory factor X5; RFXANK, RFX-associated ankyrin-containing protein; RFXAP, RFX-associated protein; RMRP, RNA component of mitochondrial RNA-
processing endoribonuclease; SLP76, SRC-homology-2-domain-containing leukocyte protein of 76 kDa; SMARCAL1, SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin a-like 1; SP110, SP110 nuclear body protein; STAT5B, signal transducer and activator of transcription 5B; TAP, transporter associated with antigen 
processing; TAPBP, TAP-binding protein; TSAD, T-cell-specific adaptor protein; ZAP70, ζ-chain-associated protein kinase of 70 kDa.
T cells, and patients have a progressive loss of B cells. 
XLF-Cernunnos is a core protein of the NHEJ pathway 
of DNA double-strand break repair. The roles of the 
Cernunnos-XLF protein are still being elucidated. Crystal-
lography suggests that it is part of the XRCC4-LIG4 complex. 
It enhances the DNA ligation activity of the XRCC4-LIG4 
complex by promoting its re-adenylation and appears to play 
an essential role in gap filling by either polymerase during 
NHEJ, suggesting that it plays a major role in aligning the 
two DNA ends in the repair complex.40,41
CD3γ deficiency
CD3γ deficiency is an AR immunodeficiency caused by 
mutations in the gene coding for T-cell surface glycoprotein 
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CD3γ chain precursors. Affected patients have decreased 
T-cell numbers and function. B cells are variably affected. 
Patients with CD3γ deficiency have varying phenotypes, 
with some having SCID-like symptoms and some having a 
benign course.42
MHC class I deficiency (Bare 
lymphocyte syndrome type I)
Most patients with MHC I expression abnormalities exhibit 
decreased or absent MHC I expression on the cell surface, 
low numbers of CD8+ T cells, and decreased NK cell-killing 
activity. However, they have normal antibody-dependent 
cell-mediated cytotoxicity.43 The clinical presentation 
is highly variable, depending upon the amount of MHC 
class I expression. Affected patients with a severe reduction 
in MHC class I expression also tend to have necrotizing 
granulomatous skin lesions.44 Some patients with MHC 
class I deficiency have defects in the transporter associated 
with antigen processing: (TAP) 1, TAP2, or tapasin. TAP1 
and TAP2 are required for peptide transport from the cytosol 
into the ER lumen, where the assembly of the MHC class I 
complex takes place. Tapasin serves as a docking site that is 
specific for interaction with class I MHC molecules, which 
is essential for peptide loading and expression. The exact 
defect has not been identified in other patients with MHC 
class I deficiency. The inheritance pattern is unclear due to 
its rarity.45
CD8 deficiency
CD8 is a TCR accessory molecule that binds to class I MHC. 
CD8 is primarily expressed on cytotoxic T cells, but is also 
found on NK cells. A single patient has been described with 
symptomatic CD8 deficiency due to a homozygous muta-
tion in the gene encoding the CD8 alpha chain (CD8α) on 
chromosome 2p12. He had recurrent sinopulmonary infec-
tions, which suggested a humoral deficiency. However, his 
immunoglobulin levels and specific antibody titers were 
normal. CD4+ T-cell, B-cell, and NK-cell percentages and 
absolute counts were normal, but CD8+ T cells were com-
pletely absent. Two younger sisters, who also had absent 
CD8+ T cells, were asymptomatic at the time of the report, 
reflecting the importance of other factors (such as epigenet-
ics and infections) in these complex diseases.46
MHC class II deficiency (Bare 
lymphocyte syndrome type II)
This is an AR disease. Both constitutive and induced MHC 
class II expressions are compromised. The exact molecular 
defects have not been identified in most patients, but 
are suspected to involve mutations in MHCII promoter 
complex DNA-binding regulatory factors (CIITA-class II 
  transactivator, RFX5, RFXAP, and RFXANK). The majority 
of identified defects are RFXANK mutations (chromosome 
19p12). The disease is more common in certain geographic 
regions (North Africa47 and Palestinians [Broides A, email 
communication, 2011]). Patients with MHC II expression 
abnormalities exhibit complete absence of MHC II expres-
sion on B cells, a normal number of B cells in peripheral 
blood,   hypogammaglobulinemia, and poor specific-antibody 
responses. In addition, CD4 lymphopenia, with a proportional 
increase in CD8, a normal number of T cells in peripheral 
blood, but with decreased in vitro T-cell response to antigens 
are observed. Class II MHC deficiency generally results in 
a clinical picture of severe combined immune deficiency. 
However, milder cases have been described.48
Interleukin-2 receptor alpha chain 
(CD25) deficiency
CD25 deficiency is extremely rare. Only a few patients have 
been described with lesions in the IL2-Rα gene encoding 
the α-chain of the IL-2 receptor. This immunodeficiency is 
characterized by normal to modestly decreased numbers 
of circulating T cells, displaying abnormal proliferation, 
but normal B-cell development. Extensive lymphocytic 
infiltration of tissues including the lung, liver, gut, and 
bone, is observed, accompanied by tissue atrophy, and 
inflammation.49 A phenotype resembling the syndromes of 
immune dysregulation, polyendocrinopathy,   enteropathy, 
and X-linked (IPEX) – a syndrome that is more often 
associated with mutations of the transcription factor 
FOXP3 – has also been described.50
Lymphocyte-specific protein 
tyrosine kinase (Lck or p56lck) 
deficiency
Initial transduction of antigen-binding signals from the 
TCR/CD3 complex is primarily dependent upon two 
  protein tyrosine kinases: Lck and ZAP-70. Several patients 
have been reported with a deficiency of Lck, which was 
activated upon engagement of the TCR-CD3 complex. 
Lck is a 56-kDa member of the Src-family tyrosine 
kinase family.   Deficiency of Lck is reported to result in 
an   immunodeficiency   characterized by selective CD4 
  lymphopenia, decreased CD28 expression on CD8 cells, 
and low, to absent   immunoglobulins. Patients demonstrate 
the typical failure to thrive that is seen in SCID.51
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ZAP-70 deficiency
ZAP-70 deficiency is a rare combined immunodeficiency 
with an AR pattern of inheritance. Zeta chain-associated 
70-kDa protein kinase (ZAP-70) is a signaling molecule 
  associated with the TCR complex, which is expressed 
primarily in T cells. Most mutations occur within the kinase 
domain of the ZAP-70 protein, and significantly affect both 
protein stability, and catalytic activity. Deficiency of ZAP-70 
(which was originally described in a Mennonite family) is 
characterized by the selective absence of circulating CD8+ 
T cells and by abundant CD4+ T cells in the peripheral blood 
that are unresponsive to TCR-mediated stimuli in vitro.52 All 
patients with ZAP-70 deficiency have normal to elevated 
numbers of circulating lymphocytes.53
ORAI1/CRACM1 and STIM1 
deficiencies
Lymphocyte activation after antigen stimulation is dependent 
upon store-operated entry of Ca2+ across the plasma membrane 
via Ca2+ release-activated Ca2+ (CRAC) channels. OraI1 or 
calcium release-activated calcium modulator 1 (CRACM1) 
is the pore-forming subunit of the CRAC   channel. Stromal 
interaction molecule 1 (STIM1) senses release of Ca2+ 
from endoplasmic reticulum stores and activates CRAC 
channels in the plasma membrane. Sustained Ca2+ influx 
induces expression of IL-2 and other cytokines. The clini-
cal phenotypes of the ORAI1 defect and of the STIM defect 
are similar. Mutations in ORAI1 on chromosome 12q24 
and STIM1 on chromosome 11q15.5 appear to have AR 
inheritance. The laboratory findings are similar for both of 
these defects. Lymphocyte counts are normal to slightly 
reduced, and immunoglobulin levels are normal to elevated. 
However, the T-cell proliferative response to mitogens and 
antigens is compromised and specific antibody response to 
vaccination is impaired. Non-progressive muscular hypotonia 
and abnormalities in dental enamel are seen in both ORAI1 
and STIM1 deficiencies. Extensive ectodermal defects 
(ectodermal dysplasia and anhydrosis) are more prominent 
in patients with ORAI1 deficiency. Unique features of 
STIM1 deficiency are severe autoimmunity and partial iris 
hypoplasia.54,55
Signal transducer and activator  
of transcription 5b (STAT5b)  
deficiency
Several patients have been identified with mutations in the 
STAT5b gene that cause a defect in the signaling pathways 
of receptors for IL-2, IL-4, macrophage colony-stimulating 
factor, and growth hormone. CD4+ CD25+ regulatory T cells 
are decreased in number in patients with STAT5b deficiency. 
Other immunologic parameters are variable, including T-, B-, 
and NK-cell levels, and T-cell proliferation. Patients present 
with signs of growth-hormone insensitivity, including short 
stature, a prominent forehead and saddle nose, and a high-
pitched voice. Associated manifestations include eczema and 
autoimmunity as well.56
Winged-helix nude (FOXN1) 
deficiency
This extremely rare disorder is caused by a homozygous 
defect in the forkhead box N1 (FOXN1) gene, which is the 
gene mutated in “nude” SCID mice. FOXN1 is a member 
of the winged-helix domain family of transcription factors. 
This protein is involved in the development of the thymus as 
well as formation of hair and nails. It also may be involved 
in brain and neural tube development. Patients with defects 
in this gene have decreased circulating T cells, mainly due 
to low levels of CD4+ T cells. T-cell proliferative responses 
to mitogens were abnormal. Congenital alopecia and nail 
dystrophy are characteristic features. Additional defects, 
including spina bifida and anencephaly, have been described 
in a fetus.57,58
Purine nucleoside phosphorylase 
(PNP) deficiency
PNP follows ADA in the purine salvage pathway, and PNP 
deficiency causes SCID because excess deoxyguanosine 
and deoxyguanosine triphosphate lead to increased apop-
tosis of lymphocytes, mainly immature T lymphocytes.59 
PNP-deficient cells do not produce uric acid and, therefore, 
low uric acid in serum (,2 mg/dL) supports the diagnosis. 
PEG-PNP is not commercialized and gene therapy is still 
experimental in mice. HSCT is the only available therapy, 
but it does not correct the severe neurological manifestations 
usually present (hypertonia, hypotonia, ataxia, psychomo-
tor delay). Autoimmunity (hemolytic anemia, autoimmune 
thrombocytopenia, neutropenia, arthritis, etc) and neoplasia 
are also frequent.59,60
CD40 and CD40 ligand deficiencies
CD40 is a molecule on the surface of B cells and   mononuclear 
cells (including dendritic cells) that interacts with its CD40 
ligand (CD40L) on the surface of activated CD4+ T cells. 
Defects in CD40L or CD40 cause defective isotype switching 
and impaired dendritic cell signaling. Mutations in CD40L 
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(CD154) are responsible for most cases of hyper-IgM (HIGM) 
syndrome.61 The principal laboratory findings of HIGM syn-
drome are low serum levels of IgG and IgA, in combination 
with normal or elevated concentrations of IgM. Circulating 
B cells are normal in number, but exclusively express cell-
surface IgM and IgD. Vaccination may elicit specific IgM 
responses. No other isotypes are produced and there is no 
B-cell memory. CD40L is located on the X chromosome, 
while the gene encoding CD40 (TNF-receptor superfamily 
member 5 or TNFRSF5) is located on chromosome 20q12-
q13.2. Mutations in this gene underlie a clinically indis-
tinguishable disorder with AR inheritance.62 Patients with 
HIGM usually present within the first two years of life with 
the combination of recurrent respiratory tract infections with 
encapsulated bacteria and opportunistic infections. Lymph-
adenopathy and hepatosplenomegaly are often present. They 
are also prone to neutropenia, thrombocytopenia, anemia, 
sclerosing cholangitis, cirrhosis, and lymphoproliferative 
disease. Increased rates of malignancy such as hepatocel-
lular, bile duct, and neuroendocrine carcinomas are also 
reported.63
Interleukin-2 tyrosine kinase (Itk) 
deficiency
Itk deficiency is characterized by lymphoproliferation and 
severe immune dysregulation following EBV infection and 
is inherited as an AR disorder. Itk is a member of the TEC 
kinase family. These proteins are important mediators of 
antigen-receptor signaling in lymphocytes, and Itk is believed 
to be the predominant TEC kinase in T cells, and one of 
the key molecules involved in NKT cell maturation and 
survival.64 Itk deficiency was recently identified in female 
siblings who presented with EBV-associated lymphopro-
liferation, an absence of NKT cells, and hemophagocytic 
lymphohistiocytosis.65
Dedicator of cytokinesis 8 (DOCK8) 
deficiency
Several patients have been identified with loss of functional 
homozygous or compound heterozygous mutations in an 
uncharacterized gene, DOCK8, which is expressed in lym-
phocytes. Most patients have low absolute lymphocyte counts, 
including low T cells; B and NK cells are also low in many 
patients. Most patients also have eosinophilia and elevated 
IgE. IgM levels are low, but many patients have increased 
IgG levels. IgG antibody responses to bacterial and viral 
antigens are variable.66 Common clinical features include 
recurrent respiratory tract infections, extensive cutaneous 
viral and bacterial (Staphylococcus aureus) infections, 
severe atopy, and susceptibility to cancer (vulvar, facial, and 
anal squamous-cell dysplasia and carcinomas, and T-cell 
lymphoma/leukemia).66
Other well-defined 
immunodeficiency syndromes
In addition to the above-described syndromes, there are other 
well-defined primary immunodeficiency disease (PID) syn-
dromes with a variable degree of immune dysfunction such 
as Wiskott–Aldrich syndrome, DNA repair defects (ataxia 
telangiectasia, Bloom and Nijmegen syndromes), and oth-
ers. Some of them can present with the typical clinical and 
laboratory features of SCID/CID. Herein, we discuss some 
of these syndromes in detail.
DiGeorge syndrome (DGS)
DGS (OMIM 188400) results from dysmorphogenesis of the 
third and fourth pharyngeal pouches during early embryo-
genesis, leading to hypoplasia or aplasia of the thymus and 
parathyroid glands. Other structures forming at the same age 
are also frequently affected, resulting in anomalies of maxilla, 
mandible, aortic arch, cardiac outflow tract, and external/
middle ear. The classical presentation of DGS is the triad 
of conotruncal cardiac anomalies, hypoplastic thymus, and 
hypocalcemia, although the phenotype is variable. Palatal 
abnormalities and developmental delay are common.
Approximately 90% of patients with DGS have spontane-
ously arising heterozygous microdeletions in   chromosome 
22q11.2. Defects in the gene encoding the T-box tran-
scription family member, TBX1, are responsible for the 
DGS   phenotype. The basis for the syndrome without the 
  characteristic deletion is often unknown. Some patients 
will have a known exposure to toxins such as isotretinoin or 
maternal alcohol ingestion. There is also a small subset that 
shows the deletion of chromosome 10p13-14.
The immunodeficiency has been characterized as either 
complete or partial, based on the level of immunologic 
  function. The minority of patients (approximately 1%) 
have a complete absence of thymic tissue and profound 
  immunodeficiency. Patients with complete DGS resemble 
patients with SCID. Atypical cases phenotypically appear 
to be similar to OS. Complete DGS is fatal if not recognized 
and treated with a thymic or HSC transplant.67
Cartilage-hair hypoplasia (CHH)
CHH (OMIM 250250) is an AR, predominantly T-cell defi-
ciency associated with metaphyseal chondrodysplasia, a form 
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of short-limb dwarfism. Associated features may include 
fine sparse hair, cellular and humoral immunodeficiencies, 
Hirschsprung disease, hematologic and skin malignancies, 
autoimmune disease, and bronchiectasis. The responsible 
gene for CHH has been mapped to 9p21-p12 and shown to 
be the gene encoding the ribonuclease mitochondrial RNA-
processing (RMRP) protein.
Phenotypic heterogeneity is great and the immunode-
ficiency is variable. Cell-mediated immunodeficiency is 
most commonly reported. SCID is known to occur in the 
setting of CHH. SCID may present with severe T- and B-cell 
functional defects, but with quantifiable cell counts, or with 
an OS phenotype. Stem-cell transplantation has resulted in 
immunologic reconstitution in some CHH patients with the 
SCID phenotype.68
Hereditary folate malabsorption 
(HFM)
HFM (OMIM 229050) is an extremely rare AR cause of 
folic acid deficiency. It presents early in life with diarrhea, 
failure to thrive, and megaloblastic anemia often accompa-
nied by leukopenia, and/or thrombocytopenia. HFM patients 
can develop progressive neurologic deterioration (ataxia, 
seizures, and mental retardation) unless they are treated 
promptly and aggressively. Family studies have shown this 
disorder to be due to mutations in a proton-coupled folate 
transporter (PCFT), resulting in abnormal folate transport 
across the gastrointestinal tract and the blood–brain   barrier. 
HFM can present with life-threatening infections due to 
profound immunological defects that may mimic SCID. The 
immune defects are fully reversible with adequate folate 
repletion.69
Hoyeraal–Hreidarsson (HH)
HH syndrome (OMIM 300240) represents a severe   variant 
of dyskeratosis congenita (DC). This rare, progressive, 
  multisystemic disorder is characterized by intrauterine 
growth retardation, microcephaly, cerebellar hypopla-
sia, mental retardation, early onset bone marrow failure, 
  progressive combined immune deficiency, and aplastic 
anemia. DC and HH result from heterogeneous telomere 
defects.70
Gene therapy
Gene therapy for SCID is still in its infancy. Virus-based 
vectors are widely used in HSC gene therapy, and have 
the ability to integrate permanently into genomic DNA, 
thus driving long-term expression of corrective genes in all 
hematopoietic lineages. To date, HSC gene therapy has been 
successfully employed in the clinic for improving clinical 
outcomes in small numbers of patients with ADA SCID and 
XL-SCID.
ADA deficiency was the first genetic disorder to be treated 
by gene therapy; however, the first cases failed to achieve 
sustained T-cell and normal ADA levels.71 Since 2000, over 
30 patients with ADA deficiency have been treated with 
gene therapy throughout the world. Most cases have shown 
successful outcomes, achieving immune reconstitution, 
restoration of thymic activity, systemic detoxification, and 
long-term engraftment.72
The possible role of gene therapy continues to evolve 
and a second trial was carried out on XL-SCID patients. To 
date, gene therapy results are available for 20 patients with 
a typical XL-SCID. Most patients have shown substantial 
improvements in clinical and immunological features. 
However, five of the 20 patients developed a T-cell acute 
leukemia 2 to 5.5 years after gene therapy. In all cases, it 
was found that the abnormal clone had one or two provirus 
integrations within a proto-oncogene locus. Many other 
genomic abnormalities were found. Accordingly, the clini-
cal trials were discontinued. Today, gene therapy is allowed 
to continue on a case-by-case basis if no other treatment is 
available.73,74
Numerous studies have been performed to understand the 
molecular basis of vector-mediated genotoxicity, with the 
aim of developing safer vectors and lower risk gene-therapy 
protocols. One such approach involves self-inactivating 
gammaretrovirus and lentivirus-based vectors, which, when 
integrated, lack enhancer and promoter sequences from the 
long terminal repeat.75 These new vectors should decrease or 
alleviate the risks of proto-oncogene activation by insertional 
mutagenesis.76
Meanwhile, vector-mediated genotoxicity has fostered 
a growing interest for alternative strategies, referred to as 
“targeted approaches,” that consist of replacing random inte-
gration of therapeutic transgenes by targeted insertion or even 
correction of the deleterious mutation. Results are beginning 
to accumulate for clinical trials using new viral vectors77 
and the first clinical trial using a targeted approach has been 
initiated.78 Although additional time is needed to evaluate, 
more precisely, the potentials and limits of each method, 
targeted approaches remain today, at least conceptually, more 
attractive than classical gene-transfer techniques.79
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